AtriCure, Inc.
Piper Sandler maintained its Overweight rating for AtriCure (ATRC) and raised its price target from $50.00 to $60.00. The company's stock is currently trading at $48.16, which GuruFocus deems 21.6% overvalued. AtriCure has a GF Score of 79/100, indicating strong overall performance, but significant insider selling has occurred recently.
Piper Sandler raised its price target for AtriCure (NASDAQ:ATRC) to $60, citing a new quality measure for atrial fibrillation treatment as a catalyst. The firm expects market penetration to increase, driving growth. AtriCure's Q2 2026 earnings beat estimates, but shares fell on cautious outlook. BTIG also raised its target to $55.
Dahlquist Karl S. (Chief Legal Officer) sold 9,370 shares of AtriCure, Inc. (ATRC) at $48.89 ($0.46M total) on 2026-08-24.
Over the past 7 days, alphai's AI scored 3 news stories mentioning ATRC (AtriCure, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent ATRC coverage spans insider activity, financial news and earnings.
In the last 30 days, ATRC insiders filed 4 SEC Form 4 transactions — no purchases and 4 sales ($971K). The most active reporter was Yuen Maggie with 1 filing.
Analyst upgrade may support short-term price appreciation.
Analyst upgrade and earnings beat suggest upside potential.
Insider sale of modest size may indicate personal liquidity need or neutral view; limited price impact expected.
Positive sentiment from target increase.
Revenue growth and device pipeline news support a modest rally.
alphai scores every news story that mentions ATRC with an AI model for sentiment and relevance, and aggregates insider trades from AtriCure, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Piper Sandler maintained its Overweight rating for AtriCure (ATRC) and raised its price target from $50.00 to $60.00. The company's stock is currently trading at $48.16, which GuruFocus deems 21.6% overvalued. AtriCure has a GF Score of 79/100, indicating strong overall performance, but significant insider selling has occurred recently.
2 min readPiper Sandler raised its price target for AtriCure (NASDAQ:ATRC) to $60, citing a new quality measure for atrial fibrillation treatment as a catalyst. The firm expects market penetration to increase, driving growth. AtriCure's Q2 2026 earnings beat estimates, but shares fell on cautious outlook. BTIG also raised its target to $55.
2 min readDahlquist Karl S. (Chief Legal Officer) sold 9,370 shares of AtriCure, Inc. (ATRC) at $48.89 ($0.46M total) on 2026-08-24.
1 min readWall Street analysts updated price targets and ratings for several companies. Baird cut Chipotle's (CMG) target to $40 and downgraded it to Neutral. HC Wainwright raised LB Pharmaceuticals' (LBRX) target to $60. BTIG increased AtriCure's (ATRC) target to $55. Baird also raised Analog Devices' (ADI) target to $675 and upgraded Darden Restaurants' (DRI) target to $250. Other notable changes include updates for Black Rock Coffee Bar (BRCB), Marti Technologies (MRT), Alkami Technology (ALKT), Chenie
2 min readSeveral biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.
3 min readAtriCure (NASDAQ:ATRC) director Maggie Yuen sold 3,500 shares on Aug. 5, 2026 for about $134,470, at a weighted average $38.42, leaving 14,015 shares. The article also cites AtriCure’s 2Q revenue up 13% to $154 million, gross margin at 77%, and a raised full-year outlook.
4 min readPrange Karen sold 3,564 shares of AtriCure, Inc. (ATRC) at $38.80 ($0.14M total) on 2026-08-05.
2 min readYuen Maggie sold 3,500 shares of AtriCure, Inc. (ATRC) at $38.42 ($0.13M total) on 2026-08-05.
1 min readDoraiswamy Vinayak (Chief Scientific Officer) sold 6,000 shares of AtriCure, Inc. (ATRC) at $38.88 ($0.23M total) on 2026-07-28.
2 min readWEHRWEIN SVEN sold 25,000 shares of AtriCure, Inc. (ATRC) at $37.84 ($0.95M total) on 2026-07-28.
1 min read
